PL2813491T3 - Pochodna cykloalkanu - Google Patents

Pochodna cykloalkanu

Info

Publication number
PL2813491T3
PL2813491T3 PL13746373T PL13746373T PL2813491T3 PL 2813491 T3 PL2813491 T3 PL 2813491T3 PL 13746373 T PL13746373 T PL 13746373T PL 13746373 T PL13746373 T PL 13746373T PL 2813491 T3 PL2813491 T3 PL 2813491T3
Authority
PL
Poland
Prior art keywords
cycloalkane derivative
cycloalkane
derivative
Prior art date
Application number
PL13746373T
Other languages
English (en)
Inventor
Tsuyoshi Shinozuka
Hiroyuki Kobayashi
Sayaka Suzuki
Kyosuke Tanaka
Hiroko Kimoto
Yuki Domon
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of PL2813491T3 publication Critical patent/PL2813491T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13746373T 2012-02-09 2013-02-08 Pochodna cykloalkanu PL2813491T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27
EP13746373.3A EP2813491B1 (en) 2012-02-09 2013-02-08 Cycloalkane derivative

Publications (1)

Publication Number Publication Date
PL2813491T3 true PL2813491T3 (pl) 2017-08-31

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13746373T PL2813491T3 (pl) 2012-02-09 2013-02-08 Pochodna cykloalkanu

Country Status (31)

Country Link
US (3) US8889741B2 (pl)
EP (2) EP3144300B1 (pl)
JP (2) JP5997710B2 (pl)
KR (1) KR20140127238A (pl)
CN (1) CN104185629B (pl)
AU (1) AU2013218592B2 (pl)
BR (1) BR112014019478A2 (pl)
CA (1) CA2864222C (pl)
CO (1) CO7151511A2 (pl)
CY (1) CY1118572T1 (pl)
DK (1) DK2813491T3 (pl)
ES (2) ES2613078T3 (pl)
HK (1) HK1203503A1 (pl)
HR (1) HRP20161713T1 (pl)
HU (2) HUE037048T2 (pl)
IL (1) IL234014A (pl)
IN (1) IN2014MN01577A (pl)
LT (1) LT2813491T (pl)
MX (1) MX349354B (pl)
NZ (1) NZ628096A (pl)
PH (2) PH12014501804A1 (pl)
PL (1) PL2813491T3 (pl)
PT (1) PT2813491T (pl)
RS (1) RS55671B1 (pl)
RU (1) RU2635354C2 (pl)
SG (1) SG11201404707VA (pl)
SI (1) SI2813491T1 (pl)
SM (1) SMT201700053B (pl)
TW (1) TWI612042B (pl)
WO (1) WO2013118854A1 (pl)
ZA (1) ZA201405801B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
RU2014121984A (ru) * 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
IN2014MN02574A (pl) 2012-05-22 2015-07-24 Genentech Inc
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
TWI630204B (zh) * 2013-03-14 2018-07-21 第一三共股份有限公司 呼吸器官疾病用藥
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
MX2016006936A (es) 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
MX2018003828A (es) 2015-09-28 2018-06-22 Genentech Inc Compuestos terapeuticos y sus metodos de uso.
BR112018008448A2 (pt) * 2015-11-06 2018-11-06 Daiichi Sankyo Company, Limited ?método para produzir um composto?
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
SG10201912216VA (en) * 2016-05-20 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
JP2019532077A (ja) * 2016-10-17 2019-11-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
US10836758B2 (en) * 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
CN110325531B (zh) * 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AU2018338098B2 (en) 2017-09-20 2024-02-22 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
PE20211066A1 (es) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos
JP2022515630A (ja) * 2018-12-26 2022-02-21 ラクオリア創薬株式会社 Nav1.7およびNav1.8遮断薬としての複素環誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
RS53941B1 (en) 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドPfizer Limited 化合物
JP5830534B2 (ja) * 2010-07-09 2015-12-09 ファイザー・リミテッドPfizer Limited 化合物
US9145407B2 (en) * 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
RU2014121984A (ru) * 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
MX349354B (es) 2017-07-24
EP2813491B1 (en) 2016-11-02
RS55671B1 (sr) 2017-06-30
TW201339152A (zh) 2013-10-01
LT2813491T (lt) 2017-02-10
US9493448B2 (en) 2016-11-15
WO2013118854A1 (ja) 2013-08-15
HUE031450T2 (en) 2017-07-28
JPWO2013118854A1 (ja) 2015-05-11
MX2014009637A (es) 2015-06-23
RU2014136463A (ru) 2016-03-27
JP5997710B2 (ja) 2016-09-28
EP2813491A1 (en) 2014-12-17
US8889741B2 (en) 2014-11-18
ES2659434T3 (es) 2018-03-15
PT2813491T (pt) 2017-02-10
NZ628096A (en) 2016-06-24
SI2813491T1 (sl) 2017-02-28
JP6154052B2 (ja) 2017-06-28
BR112014019478A2 (pt) 2019-05-28
CY1118572T1 (el) 2017-07-12
DK2813491T3 (en) 2017-02-13
ZA201405801B (en) 2015-12-23
IN2014MN01577A (pl) 2015-05-08
KR20140127238A (ko) 2014-11-03
SG11201404707VA (en) 2014-10-30
AU2013218592A1 (en) 2014-09-18
JP2017008093A (ja) 2017-01-12
TWI612042B (zh) 2018-01-21
CA2864222C (en) 2016-10-25
HRP20161713T1 (hr) 2017-02-10
PH12014501804B1 (en) 2014-11-17
PH12014501804A1 (en) 2014-11-17
CN104185629A (zh) 2014-12-03
ES2613078T3 (es) 2017-05-22
EP3144300B1 (en) 2017-12-20
CO7151511A2 (es) 2014-12-29
AU2013218592B2 (en) 2016-12-22
US20140045862A1 (en) 2014-02-13
HUE037048T2 (hu) 2018-08-28
CN104185629B (zh) 2017-10-13
US9845313B2 (en) 2017-12-19
EP3144300A1 (en) 2017-03-22
IL234014A (en) 2017-09-28
CA2864222A1 (en) 2013-08-15
IL234014A0 (en) 2014-09-30
PH12015502675A1 (en) 2017-04-24
EP2813491A4 (en) 2015-08-12
US20170001984A1 (en) 2017-01-05
HK1203503A1 (en) 2015-10-30
US20150018551A1 (en) 2015-01-15
RU2635354C2 (ru) 2017-11-13
SMT201700053B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
HK1203503A1 (en) Cycloalkane derivative
HK1248702A1 (zh) 取代的吡咯烷-2-甲酰胺
HK1200830A1 (en) Substituted pyrrolidine-2-carboxamides -2-
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1207363A1 (en) Novel indanesulfamide derivative
HK1206724A1 (en) Substituted benzothienopyrimidines
HK1203926A1 (en) Benzamide derivative
HK1213253A1 (zh) 新型吡唑衍生物
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh) 取代的咪唑並噠嗪
HK1200824A1 (en) Substituted phenylazole derivative
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-
GB201211594D0 (en) Language